טוען...
Genetic Engineering and Manufacturing of Hematopoietic Stem Cells
The marketing approval of genetically engineered hematopoietic stem cells (HSCs) as the first-line therapy for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is a tribute to the substantial progress that has been made regarding HSC engineering in t...
שמור ב:
| הוצא לאור ב: | Mol Ther Methods Clin Dev |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Gene & Cell Therapy
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5415326/ https://ncbi.nlm.nih.gov/pubmed/28480310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2017.03.003 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|